Shares of Dyax (DYAX +14.4%) pop today after Jefferies initiates the shares with a Buy rating...

|About: Dyax Corp. (DYAX)|By:, SA News Editor

Shares of Dyax (DYAX +14.4%) pop today after Jefferies initiates the shares with a Buy rating and a $6 price target. Jefferies notes that with DYAX's wholly owned marketed orphan drug asset plus a widely partnered tech platform, the stocks makes an attractive small-cap biotech play. Additionally, long-term U.S. Kalbitor sales grow steadily, while royalties from potential Japan Kalbitor sales and U.S. ramucirumab sales across an increasing number of cancer indications provide additional growth catalysts.